Zelira Therapeutics is committed to world class science and evidence-based medicine
At Zelira Therapeutics we have been committed to research from the beginning and remain dedicated to building evidence for our products through clinical trials and ongoing real-world data collection in collaboration with specialists around the world.
These studies, both completed and ongoing, continue to build the evidence base for our products and inform the design of future clinical trials. We are committed to providing doctors and patients with the data and information they would expect from any pharmaceutical product. In this way we are accelerating our products along the pathway to regulatory approval and reducing the risks and costs of our clinical development program.

Pre-clinical assets
Advanced delivery technologies (EDCDM and Enhanced CBD absorption)
Breast, brain and pancreatic cancers
Neurological conditions
2016
2017
2018
2019
2020
2021
Early Days Research
6 month only in start of 2016
published
aus
2016
Second Short Study
Second half of 2016
published
aus
2016 - 2017
First Big 2017 Study – 12 Months
Steven Wright
manuscript submitted
spain
2017 - 2018
2 long years from start of 2018
Steven Wright
completed
usa
2018 - 2020
Mid 2020 and beyond, no end date
Steven Wright
in progress
usa
2020 - Present
Full Timeline Testing Width
from the start of 2016 to end of 2021
manuscript submitted
usa
2016 - 2022
2016
2017
2018
2019
2020
2021
aus
2019 - 2020
Pharmacokinetic trial of ZTL-103 in high opioid
St Vincent’s Hospital Melbourne
manuscript submitted
aus
2019 - 2020
Open label observational study of HOPE in ASD patients
Emerald Clinics
completed
aus
2021 - 2022
Double-blind, randomised, placebo-controlled trial to evaluate ZTL-106 in treating pain from musculoskeletal injuries
La Trobe University - Sport and Exercise Medicine Research Centre in Victoria
in progress
aus
2020 - Present
2016
2017
2018
2019
2020
2021
Parkinson’s Foundation, New York, NY, USA
published
usa
2020
RWE to evaluate the effectiveness of medicinal cannabis to manage pain in high opioid users
Emerald Clinics
completed
aus
2020
Medicinal Cannabis registry of Autism patients
Children’s Hospital of Philadelphia, Pennsylvania
manuscript submitted
usa
2019 - 2020
usa
2020
RWE to evaluate the long-term effectiveness of Zenivol ® (ZTL-101) in chronic insomnia
Emerald Clinics
completed
aus
2021 - 2022
2016
2017
2018
2019
2020
2021
Anti-tumor effects of CBD and THC in pancreatic cancer
Curtin University WA
manuscript submitted
aus
2017 - 2020
aus
2018 - 2020
CBD to prevent or restore BBB dysfunction in diabetes
Curtin University WA
in progress
aus
2019 - 2021
Cannabinoids for the treatment of childhood brain tumours
Telethon Kids Institute WA
completed
aus
2016 - 2020
spain
2016 - 2020
Formulation development of ZTL-106 for treating pain from musculoskeletal injuries (Levin)
Zelira Labs
completed
usa
2020